Unblinding Risks In RTSM: What's Still Going Wrong, And How Korio Fixes It

By Chuck Harris, Founder and COO, Korio

In the high-stakes environment of clinical research, the "blind" is the bedrock of scientific validity, yet unintentional unblinding remains a persistent, silent threat within Randomization and Trial Supply Management (RTSM) workflows. When treatment assignments are prematurely exposed—whether through a misplaced kit number in an email or a manual configuration error—the fallout can trigger regulatory scrutiny, replacements for study personnel, or catastrophic loss of data. True protection requires moving beyond reactive, manual checks that are prone to human oversight. Korio addresses this by shifting from a legacy, custom-code approach to a proactive model that utilizes a dedicated "blinding engine." When this structural technology is paired with seasoned project management, the risk of "people and process" errors is significantly diminished, safeguarding study integrity from the first patient in to the final database lock.